Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1179-2027

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis ; volume:38 ; number:8 ; day:13 ; month:5 ; year:2020 ; pages:897 ; date:8.2020
PharmacoEconomics ; 38, Heft 8 (13.5.2020), 897, 8.2020

Creator: Ness, Nils-Henning
Schriefer, Dirk
Haase, Rocco
Ettle, Benjamin
Ziemssen, Tjalf

Contributor: SpringerLink (Online service)

DOI: 10.1007/s40273-020-00925-3

URN: urn:nbn:de:101:1-2020090823362644129544

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:47 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Ness, Nils-Henning
Schriefer, Dirk
Haase, Rocco
Ettle, Benjamin
Ziemssen, Tjalf
SpringerLink (Online service)

Other Objects (12)

Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis

Seasonal variation in multiple sclerosis relapse

Arbeitspapier

The Societal Costs of Inflation and Unemployment

Arbeitspapier

The societal costs of inflation and unemployment

Societal costs of sepsis in the Netherlands

Societal costs of fetal alcohol syndrome in Sweden

The societal costs of problem gambling in Sweden

Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease

Real-world healthcare resource utilization, costs, and predictors of relapse among US patients with incident schizophrenia or schizoaffective disorder

Personality disorders: the impact of severity on societal costs

Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials

Cognitive progression independent of relapse activity in different multiple sclerosis phenotypes

Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis

Seasonal variation in multiple sclerosis relapse

Arbeitspapier

The Societal Costs of Inflation and Unemployment

Arbeitspapier

The societal costs of inflation and unemployment

Societal costs of sepsis in the Netherlands

Societal costs of fetal alcohol syndrome in Sweden

The societal costs of problem gambling in Sweden

Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease

Real-world healthcare resource utilization, costs, and predictors of relapse among US patients with incident schizophrenia or schizoaffective disorder

Personality disorders: the impact of severity on societal costs

Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials

Cognitive progression independent of relapse activity in different multiple sclerosis phenotypes

Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis

Seasonal variation in multiple sclerosis relapse

Arbeitspapier

The Societal Costs of Inflation and Unemployment

Arbeitspapier

The societal costs of inflation and unemployment

Societal costs of sepsis in the Netherlands

Societal costs of fetal alcohol syndrome in Sweden

The societal costs of problem gambling in Sweden

Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease

Real-world healthcare resource utilization, costs, and predictors of relapse among US patients with incident schizophrenia or schizoaffective disorder

Personality disorders: the impact of severity on societal costs

Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials

Cognitive progression independent of relapse activity in different multiple sclerosis phenotypes

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis

Seasonal variation in multiple sclerosis relapse

The Societal Costs of Inflation and Unemployment

The societal costs of inflation and unemployment

Societal costs of sepsis in the Netherlands

Societal costs of fetal alcohol syndrome in Sweden

The societal costs of problem gambling in Sweden

Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease

Real-world healthcare resource utilization, costs, and predictors of relapse among US patients with incident schizophrenia or schizoaffective disorder

Personality disorders: the impact of severity on societal costs

Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials

Cognitive progression independent of relapse activity in different multiple sclerosis phenotypes

Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis

Seasonal variation in multiple sclerosis relapse

The Societal Costs of Inflation and Unemployment

The societal costs of inflation and unemployment

Societal costs of sepsis in the Netherlands

Societal costs of fetal alcohol syndrome in Sweden

The societal costs of problem gambling in Sweden

Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease

Real-world healthcare resource utilization, costs, and predictors of relapse among US patients with incident schizophrenia or schizoaffective disorder

Personality disorders: the impact of severity on societal costs

Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials

Cognitive progression independent of relapse activity in different multiple sclerosis phenotypes

Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis

Seasonal variation in multiple sclerosis relapse

The Societal Costs of Inflation and Unemployment

The societal costs of inflation and unemployment

Societal costs of sepsis in the Netherlands

Societal costs of fetal alcohol syndrome in Sweden

The societal costs of problem gambling in Sweden

Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease

Real-world healthcare resource utilization, costs, and predictors of relapse among US patients with incident schizophrenia or schizoaffective disorder

Personality disorders: the impact of severity on societal costs

Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials

Cognitive progression independent of relapse activity in different multiple sclerosis phenotypes

Related objects

Reset password